Opendata, web and dolomites

Vaprosep

Validation of Progranulin as Biomarker in Diagnostics and Prognosis of Sepsis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Vaprosep project word cloud

Explore the words cloud of the Vaprosep project. It provides you a very rough idea of what is the project "Vaprosep" about.

delay    guarantee    rate    strategic    agent    prove    avoidance    data    500    notified    care    detection    economic    length    solidity    mediagnost    subsequent    12    validation    clinical    therapy    sepsis    literature    successfully    multiplex    interviewed    market    reaction    biomarker    reimbursement    incidence    host    mean    time    employees    million    advantages    stay    unnecessary    disease    therapeutic    sensitive    hospital    inducing    contact    strategy    health    feasibility    inflammatory    infectious    regarding    administrative    successful    antibiotic    structured    differentiation    1000    scientific    leaders    monitoring    validated    hospitals    prognosis    infection    bodies    infrastructure    systemic    routine    icu    picture    progranulin    reduce    day    technically    excellent    course    completion    point    property    worldwide    094    patient    regulatory    complete    direct    qualified    questionnaire    intellectual    opinion    preliminary   

Project "Vaprosep" data sheet

The following table provides information about the project.

Coordinator
MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH 

Organization address
address: ASPENHAUSTRASSE 25
city: REUTLINGEN
postcode: 72770
website: www.mediagnost.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.mediagnost.de/en/news/summary-of-sme-instrument-phase-i-project-vaprosep-2/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH DE (REUTLINGEN) coordinator 50˙000.00

Map

 Project objective

Sepsis is a complex, systemic and inflammatory host reaction on an infection and with worldwide 1.5 million cases per year a health challenge. There is a strong need for a reliable biomarker like progranulin. Preliminary data prove that progranulin allows a highly sensitive and specific detection of sepsis, a monitoring of infection without time delay, prognosis regarding disease course and a differentiation between the infectious agent inducing sepsis.

Economic advantages of progranulin as biomarker are the reduction of the length of stay in the ICU (500-1000€ / day) and avoidance of unnecessary antibiotic therapy (10-500€ / day). Thus, the hospital can improve patient care and reduce therapeutic costs by a progranulin measurement for 5-10€. A mean incidence rate of 0.094% results in a 12 million euro market in the US and EU. Based on intellectual property this market is available only for Mediagnost. Successfully validated, progranulin measurement will be introduced in third level hospitals in the EU. The subsequent strategic product development includes point of care and multiplex test systems.

Mediagnost already has a technically validated test system for this biomarker available, therefore the overall objectives of this study are the clinical validation of progranulin measurement in sepsis and its implementation in clinical routine. Specifically, in phase I the economic potential of this biomarker is evaluated.

These objectives are addressed during phase I in a feasibility study including market and cost analysis. Key opinion leaders in the EU are interviewed by a structured questionnaire to evaluate scientific solidity and market potential. In direct contact to EU Notified Bodies the best regulatory strategy is evaluated. Further, literature research will complete the picture of the market and reimbursement requirements. Excellent infrastructure and highly qualified scientific and administrative employees guarantee the successful completion of this work.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VAPROSEP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VAPROSEP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

PD_Pal (2019)

Palliative care in Parkinson’s disease

Read More  

SELNET (2019)

Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary network

Read More